Saxenda denials: what the review data shows
Independent reviewers have decided 46 published cases where an insurer denied Saxenda — and they overturned the insurer 91.3% of the time. A denial for Saxenda is a starting position, not a final answer.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 35 | 94.3% |
Why plans deny Saxenda — and how appeals win
Saxenda (liraglutide) is FDA-approved for: chronic weight management. Denials that treat an on-label prescription as unproven or cosmetic are the ones reviewers reverse most readily.
Weight-loss benefit exclusions
As a dedicated anti-obesity medication, Saxenda gets swept up in category exclusions. The counter is the same as for the newer agents: obesity is a diagnosed chronic condition, and the denial letter must point to actual plan language.
“Use a newer agent” formulary steering
Some plans prefer newer weekly GLP-1s and deny daily liraglutide; others do the reverse and demand Saxenda before covering newer drugs. Either way, the prescriber's rationale for this agent — tolerability, history, dosing needs — is what the exception process weighs.
BMI and comorbidity thresholds
Coverage criteria track the label's BMI framework, and denials most often cite missing chart documentation of BMI or a weight-related comorbidity rather than any dispute about the medicine.
If the plan demands a different agent first, file a step-therapy exception with prescriber documentation of why liraglutide is the appropriate choice — prior outcomes, tolerability, or contraindications to alternatives.
What winning Saxenda appeals argue
- Document BMI history and weight-related comorbidities directly in the appeal packet — don't assume the plan pulled the chart.
- Include prior weight-management attempts (programs, medications, outcomes) to satisfy or preempt step-therapy criteria.
- If steered toward a different agent, have the prescriber state the clinical reason Saxenda fits — the published record shows reviewers take that seriously.
The published record backs the effort: 46 external-review decisions on Saxenda denials, 91.3% overturned. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Saxendawhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY